In a welcome move, CeriBell saw its Relative Strength Rating rise from 70 to 73 on Friday.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best stocks often have an 80 or higher RS Rating as they launch their biggest price moves. See if CeriBell can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
CeriBell is trading within a buy zone after breaking past a 27.71 buy point in a ipo base. Once a stock moves 5% or higher beyond the initial entry, it's considered out of buy range.
CeriBell showed 0% earnings growth in its most recent report, while sales growth came in at 48%.
CeriBell holds the No. 48 rank among its peers in the Medical-Products industry group. LeMaitre Vascular, Pro-Dex and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
